STAT+: Pharmalittle: We’re reading about a Huntington’s gene therapy, Novo’s challenges, and more
STAT News · LC · trust 36/100
UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of the latest pharma headlines in today's Pharmalittle newsletter.
Read the original at STAT News →
Open in TruthVane →